Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Observational Study of OROSEDAL in Sore Throat and Minor Oral Lesions

NCT: NCT07620353 · RECRUITING

NCT IDNCT07620353
StatusRECRUITING
Start Date2026-03-05
Completion2027-07
SponsorLaboratoires Elerte (INDUSTRY)
First posted
Last updated

Brief Summary

This prospective, multicenter, national, observational, non-interventional post-market clinical follow-up study will evaluate the performance and safety of OROSEDAL in children and adults with sore throat or minor oral lesions, including minor aphthous ulcers and histologically confirmed oral lichen planus. OROSEDAL is prescribed in routine practice before inclusion. Patients will be followed for 6 ± 1 days and will complete self-assessments of pain, swallowing discomfort, treatment use, and adverse events.

Frequently Asked Questions

What is Observational Study of OROSEDAL in Sore Throat and Minor Oral Lesions?

Observational Study of OROSEDAL in Sore Throat and Minor Oral Lesions is a clinical trial registered under NCT07620353. Current status: RECRUITING.

What is the status of NCT07620353?

The current status of NCT07620353 (Observational Study of OROSEDAL in Sore Throat and Minor Oral Lesions) is: RECRUITING.

When did Observational Study of OROSEDAL in Sore Throat and Minor Oral Lesions start?

Observational Study of OROSEDAL in Sore Throat and Minor Oral Lesions started on 2026-03-05.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.